Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606905 · ClinicalTrials.gov registry record · NA
Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage
A NA study of Miscarriage, Recurrent and Abortion, Habitual, sponsored by University of Chicago.
- Completed
- Registry status
- NA
- Development phase
- 82
- Enrollment target
- 1
- Study location
NCT00606905 is a NA study of Miscarriage, Recurrent and Abortion, Habitual that has completed, run by University of Chicago. The registered enrollment target is 82 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00606905, a NA study of Miscarriage, Recurrent and Abortion, Habitual, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
Recurrent miscarriage is a prevalent reproductive problem that affects many couples who are trying to establish a family. This clinical study will evaluate the effectiveness of intravenous immunoglobulin (IVIG) in improving the live birth rate in couples who suffer from secondary recurrent miscarriage. This study will help in providing an answer to the question of whether IVIG is helpful in secondary recurrent miscarriage.
Conditions Studied
Interventions
- BIOLOGICAL Gamimune N or Gamunex 10%
- OTHER normal saline
Study Locations (1)
Illinois
- The University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 1999-11 |
| Est. Completion | 2010-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606905
The ClinicalTrials.gov registry entry for NCT00606905 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Miscarriage, Recurrent appearing as the primary indexed condition, and to 2 interventions - of which Gamimune N or Gamunex 10% is the first listed.
NCT00606905 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00606905 about?
NCT00606905 is a clinical study titled "Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage". Recurrent miscarriage is a prevalent reproductive problem that affects many couples who are trying to establish a family. This clinical study will evaluate the effectiveness of intravenous immunoglobulin (IVIG) in improving the live birth rate in couples who suffer from secondary recurrent miscarria...
What is the current status of trial NCT00606905?
This trial is currently completed. It is a NA study. The enrollment target is 82 participants. The study started on 1999-11. Estimated completion is 2010-01.
What conditions does trial NCT00606905 study?
This clinical trial studies the following conditions: Miscarriage, Recurrent, Abortion, Habitual.
What interventions are being tested in trial NCT00606905?
The interventions under investigation include: Gamimune N or Gamunex 10% (BIOLOGICAL), normal saline (OTHER).
Who is sponsoring clinical trial NCT00606905?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00606905 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Miscarriage, Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.